Other Species / Isoforms
  NEK9 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsVLGEYER
Upstream
0 9
Treatment
  • MG132_withdrawal
NEK9 (human) ______MsVLGEYER S2-p
NEK9 (mouse) ______MsVLGEYER S2-p
NEK9 (rat) ______MSVLGEYER S2
S13-p
EYERHCDsINsDFGs
Upstream
0 9
Treatment
  • BI2536
  • nocodazole
  • thymidine
NEK9 (human) EYERHCDsINsDFGs S13-p
NEK9 (mouse) EYERHCDsINsDFGs S13-p
NEK9 (rat) EYERHCDSINSDFGS S13
S16-p
RHCDsINsDFGsEsG
Upstream
0 6
Treatment
  • nocodazole
  • thymidine
NEK9 (human) RHCDsINsDFGsEsG S16-p
NEK9 (mouse) RHCDsINsDFGsEsG S16-p
NEK9 (rat) RHCDSINSDFGSESG S16
S20-p
sINsDFGsEsGGCGD
Upstream
0 5
Treatment
  • nocodazole
  • thymidine
NEK9 (human) sINsDFGsEsGGCGD S20-p
NEK9 (mouse) sINsDFGsEsGGGGD S20-p
NEK9 (rat) SINSDFGSESGGGGD S20
S22-p
NsDFGsEsGGCGDss
0 2
NEK9 (human) NsDFGsEsGGCGDss S22-p
NEK9 (mouse) NsDFGsEsGGGGDsG S22-p
NEK9 (rat) NSDFGSESGGGGDSG S22
S28-p
EsGGCGDssPGPSAs
0 2
NEK9 (human) EsGGCGDssPGPSAs S28-p
NEK9 (mouse) EsGGGGDsGPGPSAV S28-p
NEK9 (rat) ESGGGGDSGSGPSAS S28
S29-p
sGGCGDssPGPSAsQ
Upstream
1 13
Treatment
  • nocodazole
  • thymidine
  • UV
NEK9 (human) sGGCGDssPGPSAsQ S29-p
NEK9 (mouse) sGGGGDsGPGPSAVP G29
NEK9 (rat) SGGGGDSGSGPSASP G29
S35-p
ssPGPSAsQGPRAGG
Upstream
0 2
Treatment
  • UV
NEK9 (human) ssPGPSAsQGPRAGG S35-p
NEK9 (mouse) sGPGPSAVPGPRAGG V35
NEK9 (rat) SGSGPSASPGPRAGG S35
Y52-p
AEQEELHyIPIRVLG
0 5
NEK9 (human) AEQEELHyIPIRVLG Y52-p
NEK9 (mouse) AEQEELHYIPIRVLG Y52
NEK9 (rat) AEQEELHYIPIRVLG Y51
R60-m1
IPIRVLGrGAFGEAT
0 1
NEK9 (human) IPIRVLGrGAFGEAT R60-m1
NEK9 (mouse) IPIRVLGRGAFGEAT R60
NEK9 (rat) IPIRVLGRGAFGEAT R59
T72-p
EATLYRRtEDDsLVV
0 1
NEK9 (human) EATLYRRtEDDsLVV T72-p
NEK9 (mouse) EATLYRRTEDDSLVV T72
NEK9 (rat) EATLYRRTEDDSLVV T71
S76-p
YRRtEDDsLVVWkEV
Upstream
0 4
Treatment
  • nocodazole
  • thymidine
NEK9 (human) YRRtEDDsLVVWkEV S76-p
NEK9 (mouse) YRRTEDDSLVVWKEV S76
NEK9 (rat) YRRTEDDSLVVWKEV S75
K81-ub
DDsLVVWkEVDLTRL
0 2
NEK9 (human) DDsLVVWkEVDLTRL K81-ub
NEK9 (mouse) DDSLVVWKEVDLTRL K81
NEK9 (rat) DDSLVVWKEVDLTRL K80
K191-ub
LTKANLIkLGDYGLA
0 1
NEK9 (human) LTKANLIkLGDYGLA K191-ub
NEK9 (mouse) LTKANLIKLGDYGLA K191
NEK9 (rat) LTKANLIKLGDYGLA K190
K199-ub
LGDYGLAkkLNSEYs
0 2
NEK9 (human) LGDYGLAkkLNSEYs K199-ub
NEK9 (mouse) LGDYGLAKKLNSEYS K199
NEK9 (rat) LGDYGLAKKLNSEYS K198
K200-ub
GDYGLAkkLNSEYsM
0 1
NEK9 (human) GDYGLAkkLNSEYsM K200-ub
NEK9 (mouse) GDYGLAKKLNSEYSM K200
NEK9 (rat) GDYGLAKKLNSEYSM K199
S206-p
kkLNSEYsMAEtLVG
0 1
NEK9 (human) kkLNSEYsMAEtLVG S206-p
NEK9 (mouse) KKLNSEYSMAETLVG S206
NEK9 (rat) KKLNSEYSMAETLVG S205
T210-p
SEYsMAEtLVGtPYY
Upstream
Downstream
4 0
Effects on Modified Protein
  • enzymatic activity, induced
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • NEK9 (human)
  • PLK1 (human)
Putative in vivo kinases:
  • CDK1 (human)
  • NEK9 (human)
  • PLK1 (human)
Treatment
  • BI2536
  • MG132
  • nocodazole
  • purvalanol
NEK9 (human) SEYsMAEtLVGtPYY T210-p
NEK9 (mouse) SEYSMAETLVGTPYY T210
NEK9 (rat) SEYSMAETLVGTPYY T209
T214-p
MAEtLVGtPYYMSPE
0 1
NEK9 (human) MAEtLVGtPYYMSPE T214-p
NEK9 (mouse) MAETLVGTPYYMSPE T214
NEK9 (rat) MAETLVGTPYYMSPE T213
T254-p
LKRTFDAtNPLNLCV
Upstream
0 8
Treatment
  • ischemia
NEK9 (human) LKRTFDAtNPLNLCV T254-p
NEK9 (mouse) LKRTFDAtNPLNLCV T254-p
NEK9 (rat) LKRTFDATNPLNLCV T253
K262-ub
NPLNLCVkIVQGIRA
0 9
NEK9 (human) NPLNLCVkIVQGIRA K262-ub
NEK9 (mouse) NPLNLCVkIVQGIRA K262-ub
NEK9 (rat) NPLNLCVKIVQGIRA K261
K318
RRREMEEKVTLLNAP
0 1
NEK9 (human) RRREMEEKVTLLNAP K318
NEK9 (mouse) RRREMEEkVTLLNAP K318-ac
NEK9 (rat) RRREMEEKVTLLNAP K317
K318-ub
RRREMEEkVTLLNAP
0 1
NEK9 (human) RRREMEEkVTLLNAP K318-ub
NEK9 (mouse) RRREMEEKVTLLNAP K318
NEK9 (rat) RRREMEEKVTLLNAP K317
T326-p
VTLLNAPtkRPRsst
0 2
NEK9 (human) VTLLNAPtkRPRsst T326-p
NEK9 (mouse) VTLLNAPTKRPRsst T326
NEK9 (rat) VTLLNAPTKRPRsst T325
K327-ub
TLLNAPtkRPRsstV
0 2
NEK9 (human) TLLNAPtkRPRsstV K327-ub
NEK9 (mouse) TLLNAPTKRPRsstV K327
NEK9 (rat) TLLNAPTKRPRsstV K326
S331-p
APtkRPRsstVtEAP
Upstream
0 36
Treatment
  • ischemia
  • nocodazole
  • thymidine
NEK9 (human) APtkRPRsstVtEAP S331-p
NEK9 (mouse) APTKRPRsstVtEAP S331-p
NEK9 (rat) APTKRPRsstVTEAP S330-p
S332-p
PtkRPRsstVtEAPI
Upstream
0 69
Treatment
  • ischemia
  • nocodazole
  • thymidine
NEK9 (human) PtkRPRsstVtEAPI S332-p
NEK9 (mouse) PTKRPRsstVtEAPI S332-p
NEK9 (rat) PTKRPRsstVTEAPI S331-p
T333-p
tkRPRsstVtEAPIA
Upstream
1 189
Treatment
  • gefitinib
  • nocodazole
  • wortmannin
NEK9 (human) tkRPRsstVtEAPIA T333-p
NEK9 (mouse) TKRPRsstVtEAPIA T333-p
NEK9 (rat) TKRPRsstVTEAPIA T332-p
T335-p
RPRsstVtEAPIAVV
0 13
NEK9 (human) RPRsstVtEAPIAVV T335-p
NEK9 (mouse) RPRsstVtEAPIAVV T335-p
NEK9 (rat) RPRsstVTEAPIAVV T334
Y350-p
TSRTSEVyVWGGGks
0 1
NEK9 (human) TSRTSEVyVWGGGks Y350-p
NEK9 (mouse) TSRTSEVYVWGGGKS Y350
NEK9 (rat) TSRTSEVYVWGGGKS Y349
K356-ub
VyVWGGGkstPQkLD
0 1
NEK9 (human) VyVWGGGkstPQkLD K356-ub
NEK9 (mouse) VYVWGGGKStPQKLD K356
NEK9 (rat) VYVWGGGKSTPQKLD K355
S357-p
yVWGGGkstPQkLDV
0 1
NEK9 (human) yVWGGGkstPQkLDV S357-p
NEK9 (mouse) YVWGGGKStPQKLDV S357
NEK9 (rat) YVWGGGKSTPQKLDV S356
T358-p
VWGGGkstPQkLDVI
0 10
NEK9 (human) VWGGGkstPQkLDVI T358-p
NEK9 (mouse) VWGGGKStPQKLDVI T358-p
NEK9 (rat) VWGGGKSTPQKLDVI T357
K361-ub
GGkstPQkLDVIkSG
0 1
NEK9 (human) GGkstPQkLDVIkSG K361-ub
NEK9 (mouse) GGKStPQKLDVIKsG K361
NEK9 (rat) GGKSTPQKLDVIKSG K360
K366-ub
PQkLDVIkSGCSARQ
0 7
NEK9 (human) PQkLDVIkSGCSARQ K366-ub
NEK9 (mouse) PQKLDVIKsGCsARQ K366
NEK9 (rat) PQKLDVIKSGCSARQ K365
S367
QkLDVIkSGCSARQV
0 1
NEK9 (human) QkLDVIkSGCSARQV S367
NEK9 (mouse) QKLDVIKsGCsARQV S367-p
NEK9 (rat) QKLDVIKSGCSARQV S366
S370
DVIkSGCSARQVCAG
0 1
NEK9 (human) DVIkSGCSARQVCAG S370
NEK9 (mouse) DVIKsGCsARQVCAG S370-p
NEK9 (rat) DVIKSGCSARQVCAG S369
T379
RQVCAGNTHFAVVTV
0 1
NEK9 (human) RQVCAGNTHFAVVTV T379
NEK9 (mouse) RQVCAGNtHFAVVTV T379-p
NEK9 (rat) RQVCAGNTHFAVVTV T378
K411-ub
GQLGHGDkAsYRQPK
0 1
NEK9 (human) GQLGHGDkAsYRQPK K411-ub
NEK9 (mouse) GQLGHGDKASYRQPK K411
NEK9 (rat) GQLGHGDKASYRQPK K410
S413-p
LGHGDkAsYRQPKHV
0 1
NEK9 (human) LGHGDkAsYRQPKHV S413-p
NEK9 (mouse) LGHGDKASYRQPKHV S413
NEK9 (rat) LGHGDKASYRQPKHV S412
K422-ub
RQPKHVEkLQGKAIR
0 1
NEK9 (human) RQPKHVEkLQGKAIR K422-ub
NEK9 (mouse) RQPKHVEKLQGKAIH K422
NEK9 (rat) RQPKHVEKLQGKAIH K421
K499-ub
VVVLTRNkEVYSWGC
0 3
NEK9 (human) VVVLTRNkEVYSWGC K499-ub
NEK9 (mouse) VVVLTRNKEVYSWGC K499
NEK9 (rat) VVVLTRNKEVYSWGC K498
Y509-p
YSWGCGEyGRLGLDs
0 2
NEK9 (human) YSWGCGEyGRLGLDs Y509-p
NEK9 (mouse) YSWGCGEyGRLGLDS Y509-p
NEK9 (rat) YSWGCGEYGRLGLDS Y508
S516-p
yGRLGLDsEEDyYTP
0 1
NEK9 (human) yGRLGLDsEEDyYTP S516-p
NEK9 (mouse) yGRLGLDSEEDYYTP S516
NEK9 (rat) YGRLGLDSEEDYYTP S515
Y520-p
GLDsEEDyYTPQkVD
0 7
NEK9 (human) GLDsEEDyYTPQkVD Y520-p
NEK9 (mouse) GLDSEEDYYTPQRVD Y520
NEK9 (rat) GLDSEEDYYTPQRVD Y519
K525-ub
EDyYTPQkVDVPKAL
0 4
NEK9 (human) EDyYTPQkVDVPKAL K525-ub
NEK9 (mouse) EDYYTPQRVDVPKAL R525
NEK9 (rat) EDYYTPQRVDVPKAL R524
K563-ub
CGLNEFNkLGLNQCM
0 1
NEK9 (human) CGLNEFNkLGLNQCM K563-ub
NEK9 (mouse) CGLNEFNKLGLNQCM K563
NEK9 (rat) CGLNEFNKLGLNQCM K562
K606-ub
IRTIAPGkTHTAAID
0 4
NEK9 (human) IRTIAPGkTHTAAID K606-ub
NEK9 (mouse) IRTIAPGKTHTAAID K606
NEK9 (rat) IRTIAPGKTHTAAID K605
K625-ub
LLTFGCNkCGQLGVG
0 2
NEK9 (human) LLTFGCNkCGQLGVG K625-ub
NEK9 (mouse) LLTFGCNKCGQLGVG K625
NEK9 (rat) LLTFGCNKCGQLGVG K624
K635-ub
QLGVGNYkKRLGINL
0 1
NEK9 (human) QLGVGNYkKRLGINL K635-ub
NEK9 (mouse) QLGVGNYKKRLGINL K635
NEK9 (rat) QLGVGNYKKRLGINL K634
K650-ub
LGGPLGGkQVIRVSC
0 2
NEK9 (human) LGGPLGGkQVIRVSC K650-ub
NEK9 (mouse) LGGPLGGKQVIRVSC K650
NEK9 (rat) LGGPLGGKQVIRVSC K649
T685-p
GNGRLAMtPTERPHG
0 1
NEK9 (human) GNGRLAMtPTERPHG T685-p
NEK9 (mouse) GNGRLAMTPTERPHG T685
NEK9 (rat) GNGRLAMTPTERPHG T684
K731-ac
VEKVLNSktIRsNSS
0 1
NEK9 (human) VEKVLNSktIRsNSS K731-ac
NEK9 (mouse) VEKVLNSKTIRSNSS K731
NEK9 (rat) VEKVLNSKTIRSNsS K730
K731-ub
VEKVLNSktIRsNSS
0 3
NEK9 (human) VEKVLNSktIRsNSS K731-ub
NEK9 (mouse) VEKVLNSkTIRSNSS K731-ub
NEK9 (rat) VEKVLNSKTIRSNsS K730
T732-p
EKVLNSktIRsNSSG
0 1
NEK9 (human) EKVLNSktIRsNSSG T732-p
NEK9 (mouse) EKVLNSkTIRSNSSG T732
NEK9 (rat) EKVLNSKTIRSNsSG T731
S735-p
LNSktIRsNSSGLsI
0 1
NEK9 (human) LNSktIRsNSSGLsI S735-p
NEK9 (mouse) LNSkTIRSNSSGLsI S735
NEK9 (rat) LNSKTIRSNsSGLSI S734
S737
SktIRsNSSGLsIGT
0 1
NEK9 (human) SktIRsNSSGLsIGT S737
NEK9 (mouse) SkTIRSNSSGLsIGT S737
NEK9 (rat) SKTIRSNsSGLSIGT S736-p
S741-p
RsNSSGLsIGTVFQS
0 2
NEK9 (human) RsNSSGLsIGTVFQS S741-p
NEK9 (mouse) RSNSSGLsIGTVVQS S741-p
NEK9 (rat) RSNsSGLSIGTVVQS S740
S750-p
GTVFQSSsPGGGGGG
Upstream
1 2
Treatment
  • nocodazole
  • thymidine
NEK9 (human) GTVFQSSsPGGGGGG S750-p
NEK9 (mouse) GTVVQSSSPGGGIGG S750
NEK9 (rat) GTVVQSSSPGGRIGG S749
S793-p
RGMEGLIsPtEAMGN
Upstream
0 5
Treatment
  • nocodazole
  • thymidine
NEK9 (human) RGMEGLIsPtEAMGN S793-p
NEK9 (mouse) RGMEGLIsPtEAVGN S800-p
NEK9 (rat) RGMEGLISPTEAVGN S792
T795-p
MEGLIsPtEAMGNsN
0 2
NEK9 (human) MEGLIsPtEAMGNsN T795-p
NEK9 (mouse) MEGLIsPtEAVGNsC T802-p
NEK9 (rat) MEGLISPTEAVGNSC T794
S801-p
PtEAMGNsNGASSSC
0 5
NEK9 (human) PtEAMGNsNGASSSC S801-p
NEK9 (mouse) PtEAVGNsCGASSSC S808-p
NEK9 (rat) PTEAVGNSCGASSSC S800
S827-p
EFIPMPDsPsPLsAA
Upstream
0 10
Treatment
  • nocodazole
  • thymidine
NEK9 (human) EFIPMPDsPsPLsAA S827-p
NEK9 (mouse) EFIPMPDsPAPLsAA S834-p
NEK9 (rat) EFIPMPDsPTPLSAA S826-p
S829-p
IPMPDsPsPLsAAFs
Upstream
0 3
Treatment
  • nocodazole
  • thymidine
NEK9 (human) IPMPDsPsPLsAAFs S829-p
NEK9 (mouse) IPMPDsPAPLsAAFS A836
NEK9 (rat) IPMPDsPTPLSAAFS T828
S832-p
PDsPsPLsAAFsEsE
Upstream
0 4
Treatment
  • nocodazole
  • thymidine
NEK9 (human) PDsPsPLsAAFsEsE S832-p
NEK9 (mouse) PDsPAPLsAAFSQSE S839-p
NEK9 (rat) PDsPTPLSAAFSQSE S831
S836-p
sPLsAAFsEsEKDtL
Upstream
0 3
Treatment
  • nocodazole
  • thymidine
NEK9 (human) sPLsAAFsEsEKDtL S836-p
NEK9 (mouse) APLsAAFSQSEKDTL S843
NEK9 (rat) TPLSAAFSQSEKDTL S835
S838-p
LsAAFsEsEKDtLPy
0 2
NEK9 (human) LsAAFsEsEKDtLPy S838-p
NEK9 (mouse) LsAAFSQSEKDTLPY S845
NEK9 (rat) LSAAFSQSEKDTLPY S837
T842-p
FsEsEKDtLPyEELQ
0 3
NEK9 (human) FsEsEKDtLPyEELQ T842-p
NEK9 (mouse) FSQSEKDTLPYEELQ T849
NEK9 (rat) FSQSEKDTLPYEELQ T841
Y845-p
sEKDtLPyEELQGLk
0 53
NEK9 (human) sEKDtLPyEELQGLk Y845-p
NEK9 (mouse) SEKDTLPYEELQGLK Y852
NEK9 (rat) SEKDTLPYEELQGLK Y844
K852-ub
yEELQGLkVAsEAPL
0 1
NEK9 (human) yEELQGLkVAsEAPL K852-ub
NEK9 (mouse) YEELQGLKVASEVPP K859
NEK9 (rat) YEELQGLKVASEVPP K851
S855-p
LQGLkVAsEAPLEHk
0 4
NEK9 (human) LQGLkVAsEAPLEHk S855-p
NEK9 (mouse) LQGLKVASEVPPEPQ S862
NEK9 (rat) LQGLKVASEVPPEHQ S854
K862-ub
sEAPLEHkPQVEAss
0 1
NEK9 (human) sEAPLEHkPQVEAss K862-ub
NEK9 (mouse) SEVPPEPQRAAGAWP Q869
NEK9 (rat) SEVPPEHQPAVGAWP Q861
S868-p
HkPQVEAssPRLNPA
Upstream
0 15
Treatment
  • metastatic potential
  • nocodazole
  • thymidine
NEK9 (human) HkPQVEAssPRLNPA S868-p
NEK9 (mouse) PQRAAGAWPPRLDPA W875
NEK9 (rat) HQPAVGAWPPRLNPA W867
S869-p
kPQVEAssPRLNPAV
Upstream
Downstream
1 16
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
  • phosphorylation
Treatment
  • nocodazole
NEK9 (human) kPQVEAssPRLNPAV S869-p
NEK9 (mouse) QRAAGAWPPRLDPAV P876
NEK9 (rat) QPAVGAWPPRLNPAV P868
T877-p
PRLNPAVtCAGKGtP
0 2
NEK9 (human) PRLNPAVtCAGKGtP T877-p
NEK9 (mouse) PRLDPAVPCVGKALT P884
NEK9 (rat) PRLNPAVPCVGKALT P876
T883-p
VtCAGKGtPLtPPAC
Upstream
0 2
Treatment
  • nocodazole
  • thymidine
NEK9 (human) VtCAGKGtPLtPPAC T883-p
NEK9 (mouse) gap -
NEK9 (rat) gap -
T886-p
AGKGtPLtPPACACS
Upstream
0 11
Treatment
  • nocodazole
  • thymidine
NEK9 (human) AGKGtPLtPPACACS T886-p
NEK9 (mouse) PCVGKALTSAACACS T891
NEK9 (rat) PCVGKALTSPACACS T883
K929-ub
QIFTQLQkLNKkLEG
0 1
NEK9 (human) QIFTQLQkLNKkLEG K929-ub
NEK9 (mouse) QMFTQLQKLNKKLEG K934
NEK9 (rat) QIVTQLQKLNKRLEG K926
K933-ub
QLQkLNKkLEGGQQV
0 1
NEK9 (human) QLQkLNKkLEGGQQV K933-ub
NEK9 (mouse) QLQKLNKKLEGGQQV K938
NEK9 (rat) QLQKLNKRLEGGQQV R930
S944-p
GQQVGMHskGTQTAK
Upstream
Downstream
1 11
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
Effects on Biological Processes:
  • signaling pathway regulation
Kinase, in vitro:
  • NEK9 (human)
Putative in vivo kinases:
  • NEK9 (human)
NEK9 (human) GQQVGMHskGTQTAK S944-p
NEK9 (mouse) GQQVGMHsRGTQTAK S949-p
NEK9 (rat) GQQVGMHSRGTQTAK S941
K945-ub
QQVGMHskGTQTAKE
0 1
NEK9 (human) QQVGMHskGTQTAKE K945-ub
NEK9 (mouse) QQVGMHsRGTQTAKE R950
NEK9 (rat) QQVGMHSRGTQTAKE R942
S978-p
GTDSCRPsL______
Upstream
0 8
Treatment
  • nocodazole
  • thymidine
NEK9 (human) GTDSCRPsL______ S978-p
NEK9 (mouse) GTDSCRPSL______ S983
NEK9 (rat) gap -